-
1
-
-
3242777803
-
Advances in biology of multiple myeloma: Clinical applications
-
DOI 10.1182/blood-2004-01-0037
-
Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-618 (Pubitemid 38970551)
-
(2004)
Blood
, vol.104
, Issue.3
, pp. 607-618
-
-
Hideshima, T.1
Bergsagel, P.L.2
Kuehl, W.M.3
Anderson, K.C.4
-
2
-
-
34547106018
-
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
-
DOI 10.1038/nrc2189, PII NRC2189
-
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-598 (Pubitemid 47106630)
-
(2007)
Nature Reviews Cancer
, vol.7
, Issue.8
, pp. 585-598
-
-
Hideshima, T.1
Mitsiades, C.2
Tonon, G.3
Richardson, P.G.4
Anderson, K.C.5
-
3
-
-
27244434182
-
Identification and validation of novel therapeutic targets for multiple myeloma
-
DOI 10.1200/JCO.2005.05.024
-
Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005;23:6345-6350 (Pubitemid 46218845)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.26
, pp. 6345-6350
-
-
Hideshima, T.1
Chauhan, D.2
Richardson, P.3
Anderson, K.C.4
-
4
-
-
77950810666
-
Akt as a therapeutic target in mutiple myeloma
-
abstract n S83
-
Hideshima T, Raje N. Akt as a therapeutic target in mutiple myeloma. Haematologica 2007;92 [suppl 2]:abstract n S83.
-
(2007)
Haematologica
, vol.92
, Issue.SUPPL. 2
-
-
Hideshima, T.1
Raje, N.2
-
5
-
-
75149167181
-
Future perspectives in the management of myeloma
-
abstract n S134
-
Anderson KC. Future Perspectives in the Management of Myeloma. Haematologica 2007;92 [suppl 2]:abstract n S134.
-
(2007)
Haematologica
, vol.92
, Issue.SUPPL. 2
-
-
Anderson, K.C.1
-
6
-
-
0035525792
-
The AKT kinase is activated in multiple myeloma tumor cells
-
Hsu J, Shi Y, Krajewski S, et al. The AKT kinase is activated In multiple myeloma tumor cells. Blood 2001;98:2853-2855
-
(2001)
Blood
, vol.98
, pp. 2853-2855
-
-
Hsu, J.1
Shi, Y.2
Krajewski, S.3
-
7
-
-
0037013205
-
S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6
-
DOI 10.1074/jbc.M200043200
-
Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to lnterleukin-6. J Biol Chem 2002;277:15712-15720 (Pubitemid 34967845)
-
(2002)
Journal of Biological Chemistry
, vol.277
, Issue.18
, pp. 15712-15720
-
-
Shi, Y.1
Hsu, J.-H.2
Hu, L.3
Gera, J.4
Lichtenstein, A.5
-
8
-
-
0036735346
-
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779
-
Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002;62:5027-5034 (Pubitemid 34984430)
-
(2002)
Cancer Research
, vol.62
, Issue.17
, pp. 5027-5034
-
-
Shi, Y.1
Gera, J.2
Hu, L.3
Hsu, J.-H.4
Bookstein, R.5
Li, W.6
Lichtenstein, A.7
-
9
-
-
0038281345
-
Downstream effectors of oncogenic ras in multiple myeloma cells
-
DOI 10.1182/blood-2002-08-2640
-
Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras In multiple myeloma cells. Blood 2003;101:3126-3135 (Pubitemid 36858006)
-
(2003)
Blood
, vol.101
, Issue.8
, pp. 3126-3135
-
-
Hu, L.1
Shi, Y.2
Hsu, J.-H.3
Gera, J.4
Van Ness, B.5
Lichtenstein, A.6
-
10
-
-
10244260355
-
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
-
DOI 10.1182/blood-2004-06-2281
-
Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004;104:4188-4193 (Pubitemid 39620173)
-
(2004)
Blood
, vol.104
, Issue.13
, pp. 4188-4193
-
-
Raje, N.1
Kumar, S.2
Hideshima, T.3
Ishitsuka, K.4
Chauhan, D.5
Mitsiades, C.6
Podar, K.7
Le Gouill, S.8
Richardson, P.9
Munshi, N.C.10
Stirling, D.I.11
Antin, J.H.12
Anderson, K.C.13
-
11
-
-
17444440115
-
Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone
-
DOI 10.1182/blood-2003-05-1543
-
Stromberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004;103:3138-3147 (Pubitemid 38451692)
-
(2004)
Blood
, vol.103
, Issue.8
, pp. 3138-3147
-
-
Stromberg, T.1
Dimberg, A.2
Hammarberg, A.3
Carlson, K.4
Osterborg, A.5
Nilsson, K.6
Jernberg-Wiklund, H.7
-
12
-
-
33644516582
-
Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis
-
DOI 10.1158/0008-5472.CAN-05-2447
-
Yan H, Frost P, Shi Y, et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 2006;66:2305-2313 (Pubitemid 43294944)
-
(2006)
Cancer Research
, vol.66
, Issue.4
, pp. 2305-2313
-
-
Yan, H.1
Frost, P.2
Shi, Y.3
Hoang, B.4
Sharma, S.5
Fisher, M.6
Gera, J.7
Lichtenstein, A.8
-
13
-
-
10244229652
-
In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
-
Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004;104:4181-4187
-
(2004)
Blood
, vol.104
, pp. 4181-4187
-
-
Frost, P.1
Moatamed, F.2
Hoang, B.3
-
14
-
-
33746365457
-
The mTOR inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo
-
[abstract 1496]
-
Mitsiades N, McMullan C, Poulaki V, et al. The mTOR inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo. ASH Annual Meeting Abstracts 2004 November 16 [abstract 1496], Blood 2004;104:418.
-
(2004)
ASH Annual Meeting Abstracts 2004 November 16
, vol.104
, pp. 418
-
-
Mitsiades, N.1
McMullan, C.2
Poulaki, V.3
-
15
-
-
33750072949
-
Houghton PJ. mTOR and cancer therapy
-
Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436-6446
-
(2006)
Oncogene
, vol.25
, pp. 6436-6446
-
-
Easton, J.B.1
-
16
-
-
33746637660
-
Current development of mTOR inhibitors as anticancer agents
-
DOI 10.1038/nrd2062, PII NRD2062
-
Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-688 (Pubitemid 44151605)
-
(2006)
Nature Reviews Drug Discovery
, vol.5
, Issue.8
, pp. 671-688
-
-
Faivre, S.1
Kroemer, G.2
Raymond, E.3
-
17
-
-
34347220473
-
Defining the role of mTOR in cancer
-
Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
-
(2007)
Cancer Cell
, vol.12
, pp. 9-22
-
-
Guertin, D.A.1
Sabatini, D.M.2
-
18
-
-
33947538050
-
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
-
DOI 10.1038/sj.onc.1209990, PII 1209990
-
Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1Rdependent mechanism. Oncogene 2007;26:1932-1940 (Pubitemid 46474636)
-
(2007)
Oncogene
, vol.26
, Issue.13
, pp. 1932-1940
-
-
Wan, X.1
Harkavy, B.2
Shen, N.3
Grohar, P.4
Helman, L.J.5
-
19
-
-
23844438209
-
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
-
DOI 10.1158/0008-5472.CAN-05-0917
-
Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and elF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-7058 (Pubitemid 41161231)
-
(2005)
Cancer Research
, vol.65
, Issue.16
, pp. 7052-7058
-
-
Sun, S.-Y.1
Rosenberg, L.M.2
Wang, X.3
Zhou, Z.4
Yue, P.5
Fu, H.6
Khuri, F.R.7
-
20
-
-
32944457518
-
MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
-
DOI 10.1158/0008-5472.CAN-05-2925
-
O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508 (Pubitemid 43259931)
-
(2006)
Cancer Research
, vol.66
, Issue.3
, pp. 1500-1508
-
-
O'Reilly, K.E.1
Rojo, F.2
She, Q.-B.3
Solit, D.4
Mills, G.B.5
Smith, D.6
Lane, H.7
Hofmann, F.8
Hicklin, D.J.9
Ludwig, D.L.10
Baselga, J.11
Rosen, N.12
-
21
-
-
23944481410
-
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
-
DOI 10.1200/JCO.2005.13.466
-
Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347-5356 (Pubitemid 46206988)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.23
, pp. 5347-5356
-
-
Witzig, T.E.1
Geyer, S.M.2
Ghobrial, I.3
Inwards, D.J.4
Fonseca, R.5
Kurtin, P.6
Ansell, S.M.7
Luyun, R.8
Flynn, P.J.9
Morton, R.F.10
Dakhil, S.R.11
Gross, H.12
Kaufmann, S.H.13
-
22
-
-
28344456323
-
A phase study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors
-
(Meeting Abstracts)
-
Tabernero J, Rojo F, Burns H, et al. A phase study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2005:3007.
-
(2005)
J Clin Oncol
, pp. 3007
-
-
Tabernero, J.1
Rojo, F.2
Burns, H.3
-
23
-
-
77950842339
-
Toxicology and safety pharmacology of nanoparticle albumin-bound (nab) rapamycin (ABI-009)
-
Abst 5732
-
Trieu V, De J, Yang A, et al. Toxicology and safety pharmacology of nanoparticle albumin-bound (nab) rapamycin (ABI-009). Proc Am Assoc Cancer Res (AACR) 2008;49:Abst 5732.
-
(2008)
Proc Am Assoc Cancer Res (AACR)
, vol.49
-
-
Trieu, V.1
De, J.2
Yang, A.3
-
24
-
-
42649132499
-
Protein nanoparticles as drug carriers in clinical medicine
-
Hawkins MJ, Soon-Shiong P, Desal N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876-885
-
(2008)
Adv Drug Deliv Rev
, vol.60
, pp. 876-885
-
-
Hawkins, M.J.1
Soon-Shiong, P.2
Desal, N.3
-
25
-
-
27644534999
-
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade
-
DOI 10.1158/1535-7163.MCT-05-0068
-
Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-1540 (Pubitemid 41556435)
-
(2005)
Molecular Cancer Therapeutics
, vol.4
, Issue.10
, pp. 1533-1540
-
-
Shi, Y.1
Yan, H.2
Frost, P.3
Gera, J.4
Lichtenstein, A.5
-
26
-
-
33646577479
-
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
-
Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity In human multiple myeloma cells. Blood 2006;107:4053-4062
-
(2006)
Blood
, vol.107
, pp. 4053-4062
-
-
Hideshima, T.1
Catley, L.2
Yasui, H.3
-
28
-
-
14844300115
-
An integrated approach for inference and mechanistic modeling for advancing drug development
-
DOI 10.1016/j.febslet.2005.02.012, Systems Biology
-
Aksenov SV, Church B, Dhiman A, et al. An Integrated approach for inference and mechanistic modeling for advancing drug development. FEBS Lett 2005;579:1878-1883 (Pubitemid 40342668)
-
(2005)
FEBS Letters
, vol.579
, Issue.8
, pp. 1878-1883
-
-
Aksenov, S.V.1
Church, B.2
Dhiman, A.3
Georgieva, A.4
Sarangapani, R.5
Helmlinger, G.6
Khalil, I.G.7
-
29
-
-
33747620519
-
Systems biology and combination therapy in the quest for clinical efficacy
-
DOI 10.1038/nchembio817, PII NCHEMBIO817
-
Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006;2:458-466 (Pubitemid 44266307)
-
(2006)
Nature Chemical Biology
, vol.2
, Issue.9
, pp. 458-466
-
-
Fitzgerald, J.B.1
Schoeberl, B.2
Nielsen, U.B.3
Sorger, P.K.4
-
30
-
-
39149124146
-
Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: Therapeutic implications for Parkinson's disease explained via in silico studies
-
Jagatha B, Mythri RB, Vali S, Bharath MM. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via In silico studies. Free Radio Biol Med 2008;44:907-917
-
(2008)
Free Radio Biol Med
, vol.44
, pp. 907-917
-
-
Jagatha, B.1
Mythri, R.B.2
Vali, S.3
Bharath, M.M.4
-
31
-
-
36249019785
-
Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: A dynamic model
-
DOI 10.1016/j.neuroscience.2007.08.028, PII S0306452207010135
-
Vali S, Mythri RB, Jagatha B, et al. Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 2007;149:917-930 (Pubitemid 350130291)
-
(2007)
Neuroscience
, vol.149
, Issue.4
, pp. 917-930
-
-
Vali, S.1
Mythri, R.B.2
Jagatha, B.3
Padiadpu, J.4
Ramanujan, K.S.5
Andersen, J.K.6
Gorin, F.7
Bharath, M.M.S.8
-
32
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
-
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
-
(1984)
Adv Enzyme Regul
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
-
33
-
-
33747819801
-
MTOR and cancer: Insights into a complex relationship
-
Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-734
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 729-734
-
-
Sabatini, D.M.1
-
34
-
-
33947495259
-
Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells
-
DOI 10.1038/sj.onc.1209992, PII 1209992
-
Iwamaru A, Kondo Y, Iwado E, et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy In malignant glioma cells. Oncogene 2007;26:1840-1851 (Pubitemid 46474638)
-
(2007)
Oncogene
, vol.26
, Issue.13
, pp. 1840-1851
-
-
Iwamaru, A.1
Kondo, Y.2
Iwado, E.3
Aoki, H.4
Fujiwara, K.5
Yokoyama, T.6
Mills, G.B.7
Kondo, S.8
-
35
-
-
33645112812
-
Rapamycin pre-treatment protects against apoptosis
-
Ravikumar B, Berger Z, Vacher C, O'Kane CJ, Rublnszteln DC. Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 2006;15:1209-1216
-
(2006)
Hum Mol Genet
, vol.15
, pp. 1209-1216
-
-
Ravikumar, B.1
Berger, Z.2
Vacher, C.3
O'Kane, C.J.4
Rublnszteln, D.C.5
-
36
-
-
77950795869
-
Nanoparticle albumin-bound (nab) rapamycin as an anticancer agent
-
April 1418 Los Angeles, California. Abstract 4719
-
De T, Trieu V, Yim Z, et al. Nanoparticle albumin-bound (nab) rapamycin as an anticancer agent. Presented at: 98th American Association for Cancer Research Annual Meeting 2007; April 1418, 2007; Los Angeles, California. Abstract 4719.
-
(2007)
98th American Association for Cancer Research Annual Meeting 2007
-
-
De Trieu V, T.1
Yim, Z.2
-
37
-
-
18644386513
-
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays
-
DOI 10.1038/sj.onc.1205868
-
De Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 2002;21:6848-6857 (Pubitemid 35221928)
-
(2002)
Oncogene
, vol.21
, Issue.44
, pp. 6848-6857
-
-
De Vos, J.1
Thykjaer, T.2
Tarte, K.3
Ensslen, M.4
Raynaud, P.5
Requirand, G.6
Pellet, F.7
Pantesco, V.8
Reme, T.9
Jourdan, M.10
Rossi, J.-F.11
Orntoft, T.12
Klein, B.13
-
38
-
-
0042914318
-
Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
-
DOI 10.1046/j.1365-2141.2003.04481.x
-
Hedvat CV, Comenzo RL, Teruya-Feldstein J, et al. Insights into extramedullar tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 2003; 122:728-744 (Pubitemid 37100298)
-
(2003)
British Journal of Haematology
, vol.122
, Issue.5
, pp. 728-744
-
-
Hedvat, C.V.1
Comenzo, R.L.2
Teruya-Feldstein, J.3
Olshen, A.B.4
Ely, S.A.5
Osman, K.6
Zhang, Y.7
Kalakonda, N.8
Nimer, S.D.9
|